GSK plc (NYSE:GSK) is Stamos Capital Partners L.P.’s 8th Largest Position

Stamos Capital Partners L.P. lifted its position in shares of GSK plc (NYSE:GSK) by 42.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 294,820 shares of the pharmaceutical company’s stock after buying an additional 87,630 shares during the period. GSK comprises 2.3% of Stamos Capital Partners L.P.’s investment portfolio, making the stock its 8th largest position. Stamos Capital Partners L.P.’s holdings in GSK were worth $9,971,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of GSK. Grimes & Company Inc. bought a new position in shares of GSK during the fourth quarter valued at about $4,731,000. Strategic Financial Concepts LLC purchased a new stake in GSK during the 4th quarter valued at about $4,033,000. Kempner Capital Management Inc. increased its stake in GSK by 142.7% in the 4th quarter. Kempner Capital Management Inc. now owns 183,080 shares of the pharmaceutical company’s stock worth $6,192,000 after purchasing an additional 107,648 shares during the period. Stockman Wealth Management Inc. increased its stake in GSK by 3.7% in the 4th quarter. Stockman Wealth Management Inc. now owns 217,200 shares of the pharmaceutical company’s stock worth $7,346,000 after purchasing an additional 7,683 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of GSK during the third quarter valued at approximately $3,645,000. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

NYSE:GSK opened at $34.58 on Friday. The company has a market capitalization of $71.35 billion, a P/E ratio of 21.75, a P/E/G ratio of 1.12 and a beta of 0.56. The business’s 50-day moving average is $37.52 and its 200 day moving average is $36.25. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.3932 per share. The ex-dividend date was Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.55%. GSK’s dividend payout ratio (DPR) is 100.63%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.